IMAP advises pharma quality control company Lixis on cross-border sale to SEA Vision. Pharmaceutical quality control company Lixis, to SEA Vision, a global leader in pharmaceutical inspection systems. Terms of the transaction were not disclosed.
SEA Vision is an Italian company specializing in vision and track-andtrace systems for the pharmaceutical industry, with a consolidated turnover of €60 million. Lixis is an Argentinian company with over 17 years of experience in pharmaceutical vision, control and track-andtrace systems.
The operational synergies between the companies will enable SEA Vision to become the leading group providing both software and hardware in its target market in Latin America, with a local workforce of 70 professionals. Lixis has already been collaborating with SEA Vision in the Brazilian market through the São Paulo-based subsidiary SEA Vision Latin America (SVLA).
IMAP Argentina, led by Pablo Teubal and Pedro Querio, acted as exclusive financial advisor to Lixis.